The overexpression of choline-kinase alpha (CKα) promotes aberrant choline metabolism in epithelial ovarian cancer, thus increasing phosphocholine- and total choline-containing compounds. Previous findings had shown that silencing CKα impacted cell proliferation, migration and invasion, and CKα was hypothesized to be a potential new therapeutic target for ovarian cancer.